Ivermectin trial, Oxford University



[ad_1]

Ivermectin Arm of PRINCIPLE Trial Put on Hold?

MedPage Today, Merck
“concluded that the probability of ivermectin providing a potentially safe and efficacious treatment option for SARS-CoV-2 infection is low and have prioritized internal efforts towards the development of alternate candidates that provide a higher probability of success for the treatment of COVID-19.”
“If clinical data emerge providing definitive evidence for a positive benefit-risk assessment of the use of ivermectin in COVID-19, we stand ready to provide our expertise and resources as needed,”

Ivermectin, PRINCIPLE trial

Professor Chris Butler, from the University Oxford’s Nuffield Department of Primary Care Health Sciences,

Joint Chief Investigator of the PRINCIPLE trial, said,

‘Ivermectin is readily available globally,

has been in wide use for many other infectious conditions so it’s a well-known medicine with a good safety profile,

and because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries.

International Standard Randomised Controlled Trial Number

When is the study starting and how long is it expected to run for?

March 2020 to September 2022

Favipiravir

Ivermectin

A double blind trial

Independent Data Monitoring and Safety Committee

Will pick up a signal for futility, superiority, or safety

Will let the Trial Steering Committee know

Then a final analysis can be conducted, followed by the release of results and data

[ad_2]